Valcyte® (valganciclovir hydrochloride) is a cytomegalovirus (CMV) nucleoside analogue DNA polymerase inhibitor indicated in adult patients for the prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R−]), and for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).1
Valcyte is indicated in pediatric patients for the prevention of CMV disease in kidney or heart transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R−]).1
For each of these Valcyte patient populations, learn about:
- Bioavailability and Pharmacokinetics
- Drug Interactions
- Drug Formulation
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech, Inc. does not recommend and does not endorse the content on any third-party Web sites. Your use of third-party Web sites is at your own risk and subject to the terms and conditions of use for such sites.
In order to qualify for the Valcyte® Co-pay Card, the patient may be required to pay certain out-of-pocket expenses for each treatment. The Co-pay Card program is not valid for patients whose prescription drugs are covered, in whole or in part, under Medicaid, Medicare, or any other state or federal healthcare program. Patient or guardian is responsible for reporting the receipt of all co-pay benefits or reimbursement received, to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Co-pay Card program. This card is not health insurance or a benefit plan. You must be 18 years or older to receive co-pay assistance for yourself or a minor. This Co-pay Card program is void if the card is reproduced and where prohibited by law. It is good only for Genentech products in the U.S. and Puerto Rico. The Co-pay Card program expires within 12 months from enrollment. Company reserves the right to rescind, revoke, or amend the program without notice at any time. Patient, guardian, pharmacist, prescriber and any other person using the Co-pay Card agree not to seek reimbursement for all or any part of the benefit received by the recipient through the offer. Additional Terms & Conditions apply. Please visit www.Valcyte.com for the full list of Terms & Conditions.